Revcovi fda approval?

Revcovi is a long-acting recombinant factor IX therapy (eftrenonacog alfa) approved by the FDA for people with hemophilia B. It’s designed to reduce bleeding episodes and is used for:

- Routine prophylaxis to prevent bleeds
- On-demand treatment of bleeding episodes
- Perioperative (surgical) management

Key points:
- Administration: intravenous infusion
- Dosing/frequency: generally individualized based on pharmacokinetics and bleeding history; the extended half-life often allows less frequent dosing than standard factor IX products (often weekly or every 2 weeks for many patients), but exact schedules are tailored to the patient.
- Safety: like other factor IX products, potential risks include development of inhibitors to factor IX and thromboembolic events; allergic reactions can occur. Always monitor for injection-site reactions, headaches, or signs of bleeds or inhibitors.

If you’d like, I can provide:
- The exact FDA approval date and the official labeling language
- A comparison with other hemophilia B therapies (e.g., how Revcovi differs from standard factor IX or other extended-half-life products)
- A patient-friendly summary of dosing and common side effects

What specific details would you like?